Abstract
The characteristics of lentiviral vectors (stable integration in non-dividing and dividing cells, long-term expression of the transgene, absence of immune response) make them ideal gene transfer vehicula for future gene therapy. However, the most potent lentiviral vectors are derived from highly pathogenic human viruses, such as HIV. We describe how the field has engineered lentivectors with increasing biosafety both for the lab worker and for the patient. The risk associated with state-of-the-art lentivectors is therefore minimal, although a psychological barrier to use these vectors in the clinic may still have to be overcome. Due to their increased performance, care should be taken to avoid accidental transduction of the lab worker with potential hazardous genes. The precautions which have to be taken are described in detail.
Keywords: Lentiviral Vectors, transgene, psychological barrier, immune response
Current Gene Therapy
Title: Biosafety of Lentiviral Vectors
Volume: 3 Issue: 6
Author(s): Zeger Debyser
Affiliation:
Keywords: Lentiviral Vectors, transgene, psychological barrier, immune response
Abstract: The characteristics of lentiviral vectors (stable integration in non-dividing and dividing cells, long-term expression of the transgene, absence of immune response) make them ideal gene transfer vehicula for future gene therapy. However, the most potent lentiviral vectors are derived from highly pathogenic human viruses, such as HIV. We describe how the field has engineered lentivectors with increasing biosafety both for the lab worker and for the patient. The risk associated with state-of-the-art lentivectors is therefore minimal, although a psychological barrier to use these vectors in the clinic may still have to be overcome. Due to their increased performance, care should be taken to avoid accidental transduction of the lab worker with potential hazardous genes. The precautions which have to be taken are described in detail.
Export Options
About this article
Cite this article as:
Debyser Zeger, Biosafety of Lentiviral Vectors, Current Gene Therapy 2003; 3 (6) . https://dx.doi.org/10.2174/1566523034578177
DOI https://dx.doi.org/10.2174/1566523034578177 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, which is further converted to ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers.
Programmed cell death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside
Current Pharmaceutical Design Cisplatin Analogues with an Increased Interaction with DNA: Prospects for Therapy
Current Pharmaceutical Design Zinc Oxide Nanoparticles: A Biological and Pharmaceutical Review
Nanoscience & Nanotechnology-Asia Role of Nanotechnology in Delivery of Protein and Peptide Drugs
Current Pharmaceutical Design Clinical Application of Sorafenib for Treating Hepatocellular Carcinoma and Beyond
Clinical Cancer Drugs Targeting DNA Minor Groove by Hybrid Molecules as Anticancer Agents
Current Medicinal Chemistry Place of Nanofiltration for Assuring Viral Safety of Biologicals
Current Nanoscience Bromodomain Protein-directed Agents and MYC in Small Cell Lung Cancer
Current Cancer Drug Targets Bioactive Components and Pharmacological Action of Wikstroemia indica (L.) C. A. Mey and Its Clinical Application
Current Pharmaceutical Biotechnology Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Cachexia and Herbal Medicine: Perspective
Current Pharmaceutical Design Sulfation of Drug Compounds by the Zebrafish Cytosolic Sulfotransferases (SULTs)
Drug Metabolism Letters Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus
Current Cancer Drug Targets Effects of Iron Chelation in Osteosarcoma
Current Cancer Drug Targets Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
Recent Patents on Anti-Cancer Drug Discovery Targeting CD4 to Disrupt Signaling Through Membrane Rafts: Towards a Raft-Based Therapeutics
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Toward a Personalized Use of Paclitaxel
Recent Patents on Anti-Cancer Drug Discovery Combination Therapy of Cisplatin and other Agents for Osteosarcoma: A Review
Current Cancer Therapy Reviews Neuro-toxic and Reproductive Effects of BPA
Current Neuropharmacology Thioguanine, Mercaptopurine: Their Analogs and Nucleosides as Antimetabolites
Current Pharmaceutical Design